Results 121 to 130 of about 53,280 (246)

Manejo farmacológico de las uñas psoriásicas: revisión bibliográfica [PDF]

, 2018
[Resumen] Introducción: La psoriasis es una enfermedad cutánea hereditaria, inflamatoria y crónica, con una prevalencia mundial aproximadamente de entre el 1% y el 3%.
Domínguez González, Uxía
core  

Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations

International Journal of Dermatology, EarlyView.
A panel of 18 dermatologists participated in a three‐round Delphi‐based consensus process to generate a standardized framework for the diagnosis and management of alopecia areata (AA) in Asia Pacific. Recommendations focus on practicality and clinical relevance within the regional context.
Rodney Sinclair, Chao‐Chun Yang, Wen‐Hung Chung, Rachita Dhurat, Anil Ganjoo, Saranya Khunkhet, Jinran Lin, Anchala Parthasaradhi, Hyun‐Tae Shin, Kihyuk Shin, Poonkiat Suchonwanit, Kian Teo Tan, Jyh Jong Tang, Wenyu Wu, Felix Boon‐Bin Yap, Leona Yip, Angeline Yong, Cheng Zhou   +17 more
wiley   +1 more source

Assessments of CYP‐Inhibition‐Based Drug–Drug Interactions Between Tofacitinib and Lipid‐Lowering Agents in Rats Both In Vitro and In Vivo

Pharmacology Research & Perspectives
Tofacitinib is a widely used medication for the treatment of arthritis. It has been reported that some patients experience abnormal cholesterol levels following treatment, leading to recommendations for the coadministration of lipid‐lowering drugs such ...
Hang Yang, Shuanghu Wang, Quan Zhou, Peiwu Geng, Zebei Lu, Qinrong Lin, Chunhong Chen, Yunfang Zhou, Jianping Cai, Dapeng Dai   +9 more
doaj   +1 more source

Evolving treatments for Sjögren disease: current approaches and emerging targets

Internal Medicine Journal, EarlyView.
Abstract Sjögren disease (SjD) is a prevalent systemic autoimmune condition characterised by exocrine gland dysfunction, systemic inflammation and heterogeneous organ involvement. Current management remains largely symptomatic, with no approved disease‐modifying therapies available and substantial unmet clinical need. However, advances in understanding
Mansi Bhurani, Adrian Y. S. Lee, Maureen Rischmueller, Alberta Hoi   +3 more
wiley   +1 more source

Outlook Magazine, Winter 2017 [PDF]

, 2017
https://digitalcommons.wustl.edu/outlook/1203/thumbnail ...

core   +1 more source

Two decades of biologic and JAK inhibitor prescription patterns in the western region of Melbourne

Internal Medicine Journal, EarlyView.
Abstract Background and Aim Safety concerns and medication shortages may influence prescribing practices in rheumatology. This study aimed to explore the impact of Janus kinase inhibitor (JAKi) safety warnings and the COVID‐19 pandemic on biologic and targeted‐synthetic disease‐modifying antirheumatic drug (b/tsDMARD) prescription patterns from 2002 to
Alexander Kwan, Elvina Ingrid, Sara Vogrin, Ken Luong, Fei Jin, Emma Brown, Dongzhe Li, Matthew Jiang, Keith K. T. Lim   +8 more
wiley   +1 more source

Fatigue and mood disorders are highly prevalent in patients with inflammatory bowel disease: A single‐centre, cross‐sectional study using patient‐reported outcomes

Internal Medicine Journal, EarlyView.
Abstract Background Fatigue is a common and debilitating symptom in inflammatory bowel disease (IBD), yet it remains under‐recognised in clinical practice. This study aimed to quantify fatigue among Australian patients with IBD and examine associations with disease control, psychological distress and quality of life (QoL).
Andrew Chen, Darren Wong
wiley   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

A Real-World Study of Tofacitinib in Indian Patients with Refractory Moderate-to-Severe Atopic Dermatitis, its Economic Considerations and Immunological Rationale

Indian Dermatology Online Journal
Background: The response of atopic dermatitis (AD) to different biologics and JAK inhibitors (JAKibs) is variable due to the varied immunological endotypes of AD.
Kabir Sardana, Savitha Sharath, Sumitra Kumari Meena, Ananta Khurana, Bhawuk Dhir   +4 more
doaj   +1 more source

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source